本文へ移動
cccskills
無料GitHub で公開

enda-renin-aldosterone-measurement

This skill recommends simultaneous measurement of plasma renin and aldosterone in patients with primary adrenal insufficiency (PAI) to determine the presence of mineralocorticoid deficiency. It is triggered when assessing for mineralocorticoid deficiency in PAI, such as in patients with unexplained hyponatremia, hyperkalemia, or salt craving despite glucocorticoid replacement.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.9 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Measure Plasma Renin and Aldosterone to Assess Mineralocorticoid Deficiency

STEP 1 — Gather Information

Confirm PAI diagnosis (e.g., ACTH stimulation test). Obtain morning plasma renin activity (or concentration) and aldosterone level simultaneously. Document symptoms suggestive of mineralocorticoid deficiency (salt craving, postural hypotension, edema, hyponatremia, hyperkalemia) and review medications that affect RAAS (ACE inhibitors, ARBs, spironolactone, licorice, grapefruit juice, phenytoin).

STEP 2 — Rule In / Rule Out

Is plasma renin above the upper limit of the reference range and serum aldosterone normal or low? If yes → rule in mineralocorticoid deficiency. If renin is not elevated or aldosterone is appropriately high → rule out mineralocorticoid deficiency due to PAI.

STEP 3 — Classify or Stratify

If mineralocorticoid deficiency is confirmed, assess severity: marked renin elevation with low aldosterone and electrolyte abnormalities indicates greater need for replacement; mild renin rise may warrant lower fludrocortisone dose.

STEP 4 — Decide

Initiate fludrocortisone replacement (starting dose 50–100 µg daily in adults) with normal salt intake. Monitor clinical response (symptoms, serum sodium/potassium, blood pressure) and adjust dose based on clinical assessment (salt craving, postural hypotension, edema).

Clinical Guardrails / Mimics / Pitfalls

Do not interpret renin/aldosterone without excluding RAAS‑affecting drugs (ACEi, ARBs, NSAIDs, spironolactone, licorice, grapefruit juice, phenytoin). Do not apply to secondary adrenal insufficiency (renin typically low). Do not rely on aldosterone alone; an inappropriately normal/low aldosterone with elevated renin is required. Avoid fludrocortisone in patients with uncontrolled hypertension or volume overload. Do not restrict salt intake.

Concrete Clinical Example

A 45‑year‑old woman with known PAI on glucocorticoid replacement reports fatigue, salt craving, and mild postural hypotension. Labs: Na 128 mmol/L, K 5.2 mmol/L. Plasma renin activity 35 ng/mL/hr (high), aldosterone 2 ng/dL (low‑normal). Simultaneous measurement shows elevated renin with inappropriately low aldosterone → mineralocorticoid deficiency confirmed. Start fludrocortisone 50 µg daily; after 2 weeks symptoms improve and electrolytes normalize.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する